25
Jun

AstraZeneca’s top investigators took their best case for an accelerated approval of the failed cancer drug olaparib to the FDA’s panel of outside experts on Wednesday, and they lost.

…read more

Source: UPDATED: FDA experts spurn AstraZeneca’s pitch for ovarian cancer drug olaparib

    

0 No comments